Vaccines employing DCs loaded ex vivo with tumor lysate or major histocompatibility complex class I (MHC-I) peptides for re-administration to patients have been studied for decades and have been shown to generate robust memory CD8+ T cell responses.42 Here, CD8A is linked to neoplasm.